Cargando…

Interaction between Lifestyle Changes and PNPLA3 Genotype in NAFLD Patients during the COVID-19 Lockdown

The coronavirus disease 2019 (COVID-19) lockdown dramatically changed people’s lifestyles. Diet, physical activity, and the PNPLA3 gene are known risk factors for non-alcoholic fatty liver disease (NAFLD). Aim: To evaluate changes in metabolic and hepatic disease in NAFLD patients after the COVID-19...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cinque, Felice, Cespiati, Annalisa, Lombardi, Rosa, Costantino, Andrea, Maffi, Gabriele, Alletto, Francesca, Colavolpe, Lucia, Francione, Paolo, Oberti, Giovanna, Fatta, Erika, Bertelli, Cristina, Sigon, Giordano, Dongiovanni, Paola, Vecchi, Maurizio, Fargion, Silvia, Fracanzani, Anna Ludovica
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8838646/ https://www.ncbi.nlm.nih.gov/pubmed/35276911 http://dx.doi.org/10.3390/nu14030556

Ejemplares similares

Impact of deterioration of lifestyle and PNPLA3 genotype in NALFD patients during COVID-19 lockdown
por: Cinque, F., et al.
Publicado: (2022)

An Overview of Hepatocellular Carcinoma Surveillance Focusing on Non-Cirrhotic NAFLD Patients: A Challenge for Physicians
por: Cespiati, Annalisa, et al.
Publicado: (2023)

Impact of Sarcopenia and Myosteatosis in Non-Cirrhotic Stages of Liver Diseases: Similarities and Differences across Aetiologies and Possible Therapeutic Strategies
por: Cespiati, Annalisa, et al.
Publicado: (2022)

Nutritional and Lifestyle Therapy for NAFLD in People with HIV
por: Cinque, Felice, et al.
Publicado: (2023)

The I148M PNPLA3 variant mitigates niacin beneficial effects: How the genetic screening in non-alcoholic fatty liver disease patients gains value
por: Paolini, Erika, et al.
Publicado: (2023)

PD-1/PD-L1 Immuno-Mediated Therapy in NAFLD: Advantages and Obstacles in the Treatment of Advanced Disease
por: Lombardi, Rosa, et al.
Publicado: (2022)

miRNA Signature in NAFLD: A Turning Point for a Non-Invasive Diagnosis
por: Dongiovanni, Paola, et al.
Publicado: (2018)

PNPLA3 I148M Polymorphism, Clinical Presentation, and Survival in Patients with Hepatocellular Carcinoma
por: Valenti, Luca, et al.
Publicado: (2013)

The i148m Pnpla3 polymorphism influences serum adiponectin in patients with fatty liver and healthy controls
por: Valenti, Luca, et al.
Publicado: (2012)

Genetics, Immunity and Nutrition Boost the Switching from NASH to HCC
por: Dongiovanni, Paola, et al.
Publicado: (2021)

Usefulness of fibrosis-4 (FIB-4) score and metabolic alterations in the prediction of SARS-CoV-2 severity
por: Lombardi, Rosa, et al.
Publicado: (2022)

Correction to: Usefulness of Fibrosis-4 (FIB-4) score and metabolic alterations in the prediction of SARS-CoV-2 severity
por: Lombardi, Rosa, et al.
Publicado: (2022)

TM6SF2/PNPLA3/MBOAT7 Loss-of-Function Genetic Variants Impact on NAFLD Development and Progression Both in Patients and in In Vitro Models
por: Longo, Miriam, et al.
Publicado: (2021)

Screening for NAFLD—Current Knowledge and Challenges
por: Forlano, Roberta, et al.
Publicado: (2023)

Nutrients, Genetic Factors, and Their Interaction in Non-Alcoholic Fatty Liver Disease and Cardiovascular Disease
por: Lombardi, Rosa, et al.
Publicado: (2020)

Role of Serum Uric Acid and Ferritin in the Development and Progression of NAFLD
por: Lombardi, Rosa, et al.
Publicado: (2016)

NAFLD in Polycystic Ovary Syndrome: Association with PNPLA3 and Metabolic Features
por: Recuero, Amanda Medeiros, et al.
Publicado: (2022)

Epicardial Adipose Tissue (EAT) Thickness Is Associated with Cardiovascular and Liver Damage in Nonalcoholic Fatty Liver Disease
por: Fracanzani, Anna Ludovica, et al.
Publicado: (2016)

Lack of association between peroxisome proliferator-activated receptors alpha and gamma2 polymorphisms and progressive liver damage in patients with non-alcoholic fatty liver disease: a case control study
por: Dongiovanni, Paola, et al.
Publicado: (2010)

PNPLA3 GG Genotype and Carotid Atherosclerosis in Patients with Non-Alcoholic Fatty Liver Disease
por: Petta, Salvatore, et al.
Publicado: (2013)

Renin-Angiotensin System Inhibitors, Type 2 Diabetes and Fibrosis Progression: An Observational Study in Patients with Nonalcoholic Fatty Liver Disease
por: Pelusi, Serena, et al.
Publicado: (2016)

The rs599839 A>G Variant Disentangles Cardiovascular Risk and Hepatocellular Carcinoma in NAFLD Patients
por: Meroni, Marica, et al.
Publicado: (2021)

Interaction between PNPLA3 I148M Variant and Age at Infection in Determining Fibrosis Progression in Chronic Hepatitis C
por: De Nicola, Stella, et al.
Publicado: (2014)

Correlations between PNPLA3 Gene Polymorphisms and NAFLD in Type 2 Diabetic Patients
por: Gavril, Oana Irina, et al.
Publicado: (2021)

Communicating PNPLA3 genetic risk status for NAFLD among Mexican-origin men
por: Villavicencio, Edgar A., et al.
Publicado: (2023)

Glomerular Hyperfiltration: A Marker of Fibrosis Severity in Metabolic Associated Steatotic Liver Disease in an Adult Population
por: Dalbeni, Andrea, et al.
Publicado: (2023)

High Fat Diet Subverts Hepatocellular Iron Uptake Determining Dysmetabolic Iron Overload
por: Dongiovanni, Paola, et al.
Publicado: (2015)

PNPLA3 has retinyl-palmitate lipase activity in human hepatic stellate cells
por: Pirazzi, Carlo, et al.
Publicado: (2014)

Transcriptional regulation of PNPLA3 and its impact on susceptibility to nonalcoholic fatty liver Disease (NAFLD) in humans
por: Liu, Wanqing, et al.
Publicado: (2016)

Quantitative digital pathology reveals association of cell-specific PNPLA3 transcription with NAFLD disease activity
por: Sandhu, Bynvant, et al.
Publicado: (2019)

Interaction between the PNPLA3 Gene and Nutritional Factors on NAFLD Development: The Korean Genome and Epidemiology Study
por: Oh, Sooyeon, et al.
Publicado: (2022)

PNPLA3 rs738409 Genetic Variant Inversely Correlates with Platelet Count, Thereby Affecting the Performance of Noninvasive Scores of Hepatic Fibrosis
por: Meroni, Marica, et al.
Publicado: (2023)

Hypercoagulability in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD): Causes and Consequences
por: Tripodi, Armando, et al.
Publicado: (2022)

Genetics Is of the Essence to Face NAFLD
por: Meroni, Marica, et al.
Publicado: (2021)

Liver transcriptomics highlights interleukin-32 as novel NAFLD-related cytokine and candidate biomarker
por: Baselli, Guido Alessandro, et al.
Publicado: (2020)

Gallstone Disease Is Associated with More Severe Liver Damage in Patients with Non-Alcoholic Fatty Liver Disease
por: Fracanzani, Anna Ludovica, et al.
Publicado: (2012)

Nutrition and Genetics in NAFLD: The Perfect Binomium
por: Meroni, Marica, et al.
Publicado: (2020)

PNPLA3 genotype and fibrosis-4 index predict cardiovascular diseases of Japanese patients with histopathologically-confirmed NAFLD
por: Akuta, Norio, et al.
Publicado: (2021)

PNPLA3 overexpression results in reduction of proteins predisposing to fibrosis
por: Pingitore, Piero, et al.
Publicado: (2016)

The A736V TMPRSS6 Polymorphism Influences Hepatic Iron Overload in Nonalcoholic Fatty Liver Disease
por: Valenti, Luca, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_ntndnp7avq84t58btrumgp5r9t